As part of precision medicine, it will also be necessary to identify specific biomarkers in glioblastoma that can predict treatment response or resistance to CDK9 inhibition, and once determined, these biomarkers can be used to identify subsets of patients that will benefit most from the treatment. This evidence concerns the gene CDK9 and glioblastoma.